AHA Online Opioid Education Course Available
The American Heart Association launched in December 2018 a 30 minute-long online course titled “Opioid Education for Healthcare Providers.”
All articles by Florence Chaverneff, PhD
FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
A panel discussion event held at the US Food and Drug Administration gathered patients with chronic pain and FDA officials, to reconcile concerns around prescriptions of opioid medications with the needs of these patient populations.
FDA Cracks Down on Illegal Online Sales of Opioids
The U.S. Food and Drug Administration has issued warnings to 9 online companies selling illegal opioid medications on 53 websites, in direct violation of the Federal Food, Drug, and Cosmetic Act.
Naloxone Recalled Due to Potential Health Risks
Two lots of naloxone hydrochloride injections, USP have been recalled by Hospira, Inc., due to concerns regarding the presence of particulates on the syringe plunger.
Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Helping to End Addiction: NIH Initiative Addresses Opioid Epidemic
National Institutes of Health Director, Francis Collins, MD, PhD, announced on April 4, 2018 the launch of the Helping to End Addiction Long-Term Initiative.
Asthma, allergic rhinitis prevalence with long-term opioid use
Patients with opioid dependence or abuse may exhibit a higher prevalence of asthma compared with the general population.
NASEM report outlines strategy to combat opioid epidemic
The FDA commissioned the report to provide an update on current evidence on research, care, and education in the pain field, and to identify actionable measures for the FDA to more adequately address the ongoing opioid epidemic.
CDC’s opioid guideline prompts clinician concerns
The recently released CDC guidelines on opioid prescribing remain a topic of debate.
Cannabis health risks and benefits: a report from NASEM
Cannabis health end points include therapeutic effects, cardiometabolic risk, mental health, respiratory disease, and substance abuse.
Next post in Pain Information Center
